| " CGP 56697 is an effective, well-tolerated treatment for uncomplicated falciparum malaria but for this dosing regimen the recrudescence rate is unacceptablyhigh (18%)." | ( The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France.
Barette, S; Bernard, J; Bouchaud, O; Danis, M; Delmont, J; Gathmann, I; Gras, C; Malvy, D; Mull, R; Touze, JE; van Agtmael, M, 1999) | 0.3 |
| "Electrocardiograms (ECGs) were recorded before dosing and repeatedly thereafter." | ( Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers.
Bindschedler, M; Ezzet, F; Lefèvre, G; Meyer, I; Schaeffer, N; Thomsen, MS, 2000) | 0.31 |
| " Electrocardiograms (ECGs) were recorded from 48 hours before dosing until 48 hours thereafter." | ( Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants.
Bindschedler, M; Degen, P; Lefèvre, G; Sioufi, A, 2002) | 0.31 |
| " The aim of this study was to describe the dose-response relationship between coadministration of fat and relative lumefantrine bioavailability, in order to determine the minimum amount of fat necessary to optimize absorption." | ( How much fat is necessary to optimize lumefantrine oral bioavailability?
Annerberg, A; Ashley, EA; Brockman, A; Kham, A; Lindegårdh, N; Nosten, F; Singhasivanon, P; Stepniewska, K; White, NJ, 2007) | 0.34 |
| "A dose-response relationship was demonstrated between the volume of soya milk administered and lumefantrine bioavailability." | ( How much fat is necessary to optimize lumefantrine oral bioavailability?
Annerberg, A; Ashley, EA; Brockman, A; Kham, A; Lindegårdh, N; Nosten, F; Singhasivanon, P; Stepniewska, K; White, NJ, 2007) | 0.34 |
| " Health facility and health worker readiness improved from 2004 to 2006: availability of artemether-lumefantrine from 51% (48/94) to 60% (62/104), presence of artemether-lumefantrine dosage wall charts from 20% (19/94) to 75% (78/104), possession of guidelines from 58% (60/103) to 92% (124/135), and provision of in-service training from 25% (26/103) to 41% (55/135)." | ( Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study.
Chanda, P; Hamer, DH; Ndhlovu, M; Simon, JL; Sipilanyambe, N; Snow, RW; Zurovac, D, 2007) | 0.34 |
| " Taking an appropriate dosage and providing patients with proper instructions on taking the drug concurrently with fatty food are required for effective treatment with artemether-lumefantrine." | ( First case of treatment failure of artemether-lumefantrine in a Japanese traveler with imported falciparum malaria.
Kano, S; Kato, Y; Kudo, K; Mizuno, Y, 2009) | 0.35 |
| " These trials have involved more than 3,500 patients (including over 2,000 children), and led to identification of a six-dose, three-day regimen as the optimal dosing strategy for AL in uncomplicated falciparum malaria." | ( Coartem: the journey to the clinic.
Premji, ZG, 2009) | 0.35 |
| " The pharmacokinetics of artemether or lumefantrine are similar in children, when dosed according to their body weight, compared with adults." | ( Understanding the pharmacokinetics of Coartem.
Djimdé, A; Lefèvre, G, 2009) | 0.35 |
| " HWs almost always dosed AL correctly and gave accurate dosing instructions to patients; however, other aspects of counseling needed improvement." | ( Quality of malaria case management at outpatient health facilities in Angola.
de León, GF; Mihigo, J; Miller, NP; Rowe, AK; Santelli, AC; Van-Dúnem, P, 2009) | 0.35 |
| " Dosage was incorrect in 26." | ( [Management of malaria in Benin: evaluation of the practices of healthcare professionals following the introduction of artemisinin derivatives].
Abdillahi, A; Kinde-Gazard, D; Massougbodji, A; Nahum, A; Ogouyemi-Hounto, A, 2009) | 0.35 |
| " The dosing pictogram and clustering of tablets within the blister packs was considered helpful by 91." | ( Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania.
Genton, B; Kabanywanyi, AM; Kasim, P; King'eng'ena, S; Lengeler, C; Mulure, N; Schlienger, R, 2010) | 0.36 |
| "Factors contributing to adherence were likely to be helpful packaging, pictorial dosing instructions and patients' conviction that AL is effective." | ( Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania.
Genton, B; Kabanywanyi, AM; Kasim, P; King'eng'ena, S; Lengeler, C; Mulure, N; Schlienger, R, 2010) | 0.36 |
| "Adherence to the dosing regimen and timing of AL administration was very good." | ( Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania.
Genton, B; Kabanywanyi, AM; Kasim, P; King'eng'ena, S; Lengeler, C; Mulure, N; Schlienger, R, 2010) | 0.36 |
| " Mothers' knowledge and reporting of ALu's dosage was, in many cases, inconsistent with the recommended dosage schedule for children." | ( Community response to artemisinin-based combination therapy for childhood malaria: a case study from Dar es Salaam, Tanzania.
Kamat, VR; Nyato, DJ, 2010) | 0.36 |
| "To compare, in a phase IV trial, the efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) dosed at 300 and 600 mg of amodiaquine per tablet to artemether-lumefantrine (Coartem) for the treatment of Plasmodium falciparum uncomplicated malaria in Ivory Coast and Senegal." | ( Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast.
Djoman, K; Faye, B; Gaye, O; Ndiaye, JL; Ndiaye, PS; Offianan, AT; Penali, L; Sylla, K; Tine, RC; Touré, W, 2010) | 0.36 |
| " After excluding genetic host factors by genotyping potentially relevant cytochrome P450 loci, the high number of treatment failures in our study is best explained by poor adherence to complex dosing regimens in combination with insufficient fat supplementation, which are both crucial parameters for the outcome of Coartem treatment." | ( Treatment with coartem (artemether-lumefantrine) in Papua New Guinea.
DaRe, JT; Felger, I; Kiniboro, B; Lin, E; Mehlotra, RK; Mueller, I; Schoepflin, S; Zimmerman, PA, 2010) | 0.36 |
| " The system covered stocks of the four different dosage packs of artemether-lumefantrine (AL) and quinine injectable." | ( SMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology.
Barrington, J; Kungulwe, S; Mwafongo, W; Ward, P; Wereko-Brobby, O, 2010) | 0.36 |
| " Because of concerns about the complex dosing schedule, we assessed patient adherence to AL 2 years after routine implementation." | ( Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi.
Ali, D; Filler, SJ; Jafali, J; Kachur, SP; Luka, M; Mace, KE; Mathanga, DP; Mwandama, D; Sande, J; Skarbinski, J, 2011) | 0.37 |
| "Overall, adherence to AL was found to be low in both Garissa and Bunyala districts, with patient knowledge of the AL dosing regimen found to be the strongest predictor of adherence." | ( Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts, Kenya.
Allan, R; Cowley, A; Hoibak, S; Juma, E; Lawford, H; Munga, S; O'Reilly, L; Snow, RW; Vulule, J; Zurovac, D, 2011) | 0.37 |
| " The age-based dosage schedule and lack of adherence to ALu treatment guidelines by health facility staff may explain both the huge variability in observed lumefantrine concentrations and the lack of difference in concentrations between the two groups." | ( Adherence to artemether/lumefantrine treatment in children under real-life situations in rural Tanzania.
Gustafsson, LL; Kakoko, D; Mahindi, M; Petzold, M; Premji, Z; Simba, DO; Tomson, G, 2012) | 0.38 |
| " In the three AL body weight dosing groups (5 to < 15 kg, 15 to < 25 kg and 25 to < 35 kg), 80% of patients were aged 10-50 months, 46-100 months and 90-147 months, respectively." | ( Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges.
Bashraheil, M; Bassat, Q; González, R; Kipkeu, C; Lefèvre, G; Lyimo, J; Machevo, S; Maiga, H; Mårtensson, A; Menéndez, C; Nahum, A; Nwaiwu, O; Ogutu, B; Ouma, P; Ubben, D; Walter, V, 2011) | 0.37 |
| "Efficacy of AL in uncomplicated falciparum malaria is similar across body weight dosing groups as currently recommended in the label with no clinically relevant differences in safety or tolerability." | ( Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges.
Bashraheil, M; Bassat, Q; González, R; Kipkeu, C; Lefèvre, G; Lyimo, J; Machevo, S; Maiga, H; Mårtensson, A; Menéndez, C; Nahum, A; Nwaiwu, O; Ogutu, B; Ouma, P; Ubben, D; Walter, V, 2011) | 0.37 |
| " Although adherence to artemether-lumefantrine has been described as a potential problem due to the complicated dosing schedule, studies have described clinical cure rates similar to those of other antimalarials." | ( Artemether-lumefantrine: an option for malaria.
King, ST; Robinson, J; Stover, KR, 2012) | 0.38 |
| " However, the observed modest changes probably do not warrant dosage adjustment during co-administration of AL with EFV." | ( Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.
Aweeka, FT; Dorsey, G; Havlir, D; Huang, L; Lizak, P; Marzan, F; Parikh, S; Rosenthal, PJ, 2012) | 0.38 |
| "Mechanistic within-host models relating blood anti-malarial drug concentrations with the parasite-time profile help in assessing dosing schedules and partner drugs for new anti-malarial treatments." | ( Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development.
Charman, SA; Gamo-Benito, J; Humberstone, A; Jamsen, KM; McCaw, J; Moehrle, J; Price, RN; Simpson, JA; Smith, K; Zaloumis, S, 2012) | 0.38 |
| " Patients were randomized (2:1) to pyronaridine-artesunate granules (60/20 mg) once daily or artemether-lumefantrine crushed tablets (20/120 mg) twice daily, both dosed by bodyweight, orally (liquid suspension) for three days." | ( Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial.
Bhatt, KM; Borghini-Fuhrer, I; Bustos, MD; de Salazar, PM; Doumbo, OK; Duparc, S; Fleckenstein, L; Kayentao, K; Kimani, J; Kokolomami, JH; Offianan, AT; Ouédraogo, A; Pénali, LK; Quicho, F; Ramharter, M; Shin, CS; Tiono, AB; Tshefu, AK, 2012) | 0.38 |
| " The current study evaluated providers' knowledge and practices of treatment policy and dosing regimens with AL and quinine in the public, private and not-for-profit drug outlets." | ( Provider knowledge of treatment policy and dosing regimen with artemether-lumefantrine and quinine in malaria-endemic areas of western Kenya.
Abong'o, BO; Ombaka, JH; Onyango, RO; Ouma, C; Watsierah, CA, 2012) | 0.38 |
| " Information on provider in-service training, knowledge (qualification, treatment policy, dosing regimen, recently banned anti-malarials) and on practices (request for written prescription, prescription of AL, selling partial packs and advice given to patients after prescription), was collected." | ( Provider knowledge of treatment policy and dosing regimen with artemether-lumefantrine and quinine in malaria-endemic areas of western Kenya.
Abong'o, BO; Ombaka, JH; Onyango, RO; Ouma, C; Watsierah, CA, 2012) | 0.38 |
| "Public-sector providers have higher knowledge on treatment policy and dosing regimen on recommended anti-malarials." | ( Provider knowledge of treatment policy and dosing regimen with artemether-lumefantrine and quinine in malaria-endemic areas of western Kenya.
Abong'o, BO; Ombaka, JH; Onyango, RO; Ouma, C; Watsierah, CA, 2012) | 0.38 |
| " Fatty diet requirements for optimal absorption, pregnancy-induced changes in pharmacokinetics, pregnancy-related anorexia and food taboos, and emerging reduced parasite sensitivity to artemisinin, challenges optimal artemether-lumefantrine dosing and efficacy during pregnancy." | ( Use of artemether-lumefantrine to treat malaria during pregnancy: what do we know and need to know?
Adam, I; Mutabingwa, TK, 2013) | 0.39 |
| " Peak concentrations (Cmax ) and area under concentration-time curve restricted to 48 hr after single dosing (AUC(0-48) ) were selected for relative bioavailability evaluations using confidence interval approach for average bioequivalence." | ( Comparable lumefantrine oral bioavailability when co-administered with oil-fortified maize porridge or milk in healthy volunteers.
Beck, O; Gustafsson, LL; Hellgren, U; Jerling, M; Mahindi, M; Mwebaza, N; Ntale, M; Obua, C; Waako, P, 2013) | 0.39 |
| " Dosing on body weight appears justified." | ( Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.
Ariey, F; Beck, HP; Buclin, T; Csajka, C; Decosterd, LA; Duong, S; Genton, B; Guidi, M; Kabanywanyi, AM; Mercier, T; Olliaro, P; Staehli Hodel, EM; Zanolari, B, 2013) | 0.39 |
| " We assessed the dose-response association of single-dose primaquine for gametocyte clearance and for safety in P falciparum malaria." | ( Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial.
Bousema, T; Bradley, J; Drakeley, C; Eziefula, AC; Gabagaya, G; Grignard, L; Kamya, M; Lanke, KH; Mpimbaza, A; Nsobya, S; Owaraganise, A; Staedke, SG; Wanzira, H; Webb, EL; White, NJ; Yeung, S, 2014) | 0.4 |
| "Use of artemisinin-based combination therapy (ACT), such as artemether-lumefantrine (AL), requires a strict dosing schedule that follows the drugs' pharmacokinetic properties." | ( Correct dosing of artemether-lumefantrine for management of uncomplicated malaria in rural Tanzania: do facility and patient characteristics matter?
Amuri, B; de Savigny, D; Kachur, SP; Kajungu, D; Khatib, RA; Kuepfer, I; Masanja, IM; Selemani, M; Skarbinski, J, 2013) | 0.39 |
| " The outcome was correct dosing of AL based on age and weight." | ( Correct dosing of artemether-lumefantrine for management of uncomplicated malaria in rural Tanzania: do facility and patient characteristics matter?
Amuri, B; de Savigny, D; Kachur, SP; Kajungu, D; Khatib, RA; Kuepfer, I; Masanja, IM; Selemani, M; Skarbinski, J, 2013) | 0.39 |
| "7% of patients received correct dosing by weight alone and 78." | ( Correct dosing of artemether-lumefantrine for management of uncomplicated malaria in rural Tanzania: do facility and patient characteristics matter?
Amuri, B; de Savigny, D; Kachur, SP; Kajungu, D; Khatib, RA; Kuepfer, I; Masanja, IM; Selemani, M; Skarbinski, J, 2013) | 0.39 |
| "Although malaria treatment guidelines indicate AL dosing can be prescribed based on age or weight of the patient, findings from this study show that patients within the middle age and weight dosing bands were least likely to receive a correct dose by either measure." | ( Correct dosing of artemether-lumefantrine for management of uncomplicated malaria in rural Tanzania: do facility and patient characteristics matter?
Amuri, B; de Savigny, D; Kachur, SP; Kajungu, D; Khatib, RA; Kuepfer, I; Masanja, IM; Selemani, M; Skarbinski, J, 2013) | 0.39 |
| " The development of appropriate pragmatic dosing regimens for low-resource settings or community-based use is not formally regulated, even though these may alter factors which can substantially affect individual patient and population level outcome, such as drug exposure, patient adherence and the spread of drug resistance and can affect a drug's reputation and its eventual therapeutic lifespan." | ( Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.
Hastings, IM; Hayes, DJ; Hodel, EM; Kay, K; Terlouw, DJ, 2014) | 0.4 |
| "An in silico pharmacological model of anti-malarial drug treatment with the pharmacokinetic/pharmacodynamic profiles of artemether-lumefantrine (AM-LF, Coartem®) and dihydroartemisinin-piperaquine (DHA-PPQ, Eurartesim®) was constructed to assess the potential impact of programmatic factors, including regionally optimized, age-based dosing regimens, poor patient adherence, food effects and drug resistance on treatment outcome at population level, and compared both drugs' susceptibility to these factors." | ( Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.
Hastings, IM; Hayes, DJ; Hodel, EM; Kay, K; Terlouw, DJ, 2014) | 0.4 |
| "Compared with DHA-PPQ, therapeutic effectiveness of AM-LF seems more robust to factors affecting drug exposure, such as age- instead of weight-based dosing or poor adherence." | ( Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.
Hastings, IM; Hayes, DJ; Hodel, EM; Kay, K; Terlouw, DJ, 2014) | 0.4 |
| " These factors determine the adherence to the dosing schedules during the treatment course and thus the evaluation of the subsidy policy, its implementation and role in malaria burden in this region is compulsory." | ( Access to artemisinin-based combination therapy (ACT) and quinine in malaria holoendemic regions of western Kenya.
Ouma, C; Watsierah, CA, 2014) | 0.4 |
| " This result relies on the assumption that compliance to treatment with DhP is higher than that with AL due to its relatively simple once-a-day dosage regimen." | ( Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania.
Mori, AT; Ngalesoni, F; Norheim, OF; Robberstad, B, 2014) | 0.4 |
| "Adherence to anti-malarial dosing schedules is essential to ensure effective treatment." | ( Perceptions and utilization of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine in young children in the Chikhwawa District of Malawi: a mixed methods study.
Ewing, VL; Kapinda, A; Lalloo, DG; Pace, C; Richards, E; Terlouw, DJ; Tolhurst, R, 2015) | 0.42 |
| " While the sweet taste of dispersible AL may have reduced conflict between the child and caregiver, sub-optimal dosing due to medication loss remained a problem and overall adherence was greater among those receiving DHA-PPQ, which requires fewer doses." | ( Perceptions and utilization of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine in young children in the Chikhwawa District of Malawi: a mixed methods study.
Ewing, VL; Kapinda, A; Lalloo, DG; Pace, C; Richards, E; Terlouw, DJ; Tolhurst, R, 2015) | 0.42 |
| " We investigated the effect of dosing strategy on efficacy in a pooled analysis from trials done in a wide range of malaria-endemic settings." | ( The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data.
, 2015) | 0.42 |
| " Hence, dosing recommendations cannot be made in infants <5 kg as implications for toxicity are unknown." | ( Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem®).
Alao, MJ; Cousin, M; Duparc, S; Hamed, K; Jain, JP; Lefèvre, G; Lingani, M; Meremikwu, M; Ogutu, B; Ouedraogo, A; Tinto, H; Tiono, AB; Tshefu, A, 2015) | 0.42 |
| " Malaria patients rarely contain more than 10(12) parasites, while the standard dosing regimens allow approximately 1 in 10(10) parasites to survive artemisinin treatment." | ( Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness.
Hastings, IM; Hodel, EM; Kay, K, 2015) | 0.42 |
| " These results support additional studies of artemisinin dosing and duration in CMV infection." | ( Effect of artemether-lumefantrine (Coartem) on cytomegalovirus urine viral load during and following treatment for malaria in children.
Arav-Boger, R; Barger-Kamate, B; Djimde, A; Forman, M; Haidara, AS; Maiga, H; Sangare, CO; Vaidya, D, 2016) | 0.43 |
| " Using a combination of CD3+, with either the Minilab or TruScan, to screen for medicine quality will allow for complete examination of both the dosage units and the packaging to decide whether it is authentic or counterfeit." | ( Assessment of the effectiveness of the CD3+ tool to detect counterfeit and substandard anti-malarials.
Batson, JS; Bempong, DK; Lukulay, PH; Ranieri, N; Satzger, RD; Verbois, L, 2016) | 0.43 |
| " For those on EFV, close clinical follow-up for recurrent malaria following artemether-lumefantrine treatment, along with the study of modified dosing regimens that provide higher exposure, is warranted." | ( Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.
Achan, J; Aweeka, FT; Gao, Q; Huang, L; Kajubi, R; Kakuru, A; Kiconco, S; Li, F; Mwebaza, N; Parikh, S; Ssebuliba, J; Were, M, 2016) | 0.43 |
| " Our report warrants the need to establish optimal dosing of AL in adults and to alert clinicians about the importance of informing patients regarding the risk of parasites reappearing weeks after AL treatment." | ( High Rate of Treatment Failures in Nonimmune Travelers Treated With Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria in Sweden: Retrospective Comparative Analysis of Effectiveness and Case Series.
Asghar, M; Färnert, A; Gustafsson, LL; Hellgren, U; Homann, MV; Jovel, I; Pohanka, A; Sondén, K; Vieira da Silva, A; Wyss, K, 2017) | 0.46 |
| "5 mg can make dosing convenient in children." | ( Assessment of Efficacy and Safety of Arterolane Maleate-Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Rando
Anvikar, AR; Behra, N; Das, RR; Gaye, O; Jalali, RK; Maheshwar, AV; Mishra, P; Mwapasa, V; Nasa, A; Roy, A; Sagara, I; Sharma, P; Sharma, SK; Thompson, R; Toure, OA; Tshefu, AK; Valecha, N, 2017) | 0.46 |
| " All treatments were once-daily or twice-daily tablets or granules given orally and dosed by bodyweight over 3 days at the study centre." | ( Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
, 2018) | 0.48 |
| " falciparum malaria were randomly assigned in a 1:1 ratio to orally receive pyronaridine-artesunate or artemether-lumefantrine, dosed according to bodyweight, for 3 days." | ( Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial.
Choy, F; Makio, N; Mens, P; Okach, S; Omweri, G; Osoti, V; Roth, JM; Sawa, P; Schallig, HDFH, 2018) | 0.48 |
| " The aim of this study was to investigate the pharmacokinetic and pharmacodynamic properties of lumefantrine and the pharmacokinetic properties of its metabolite, desbutyl-lumefantrine, in order to inform optimal dosing regimens in all patient populations." | ( Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
Ashley, EA; Ashton, M; Aweeka, F; Bakshi, R; Barnes, KI; Björkman, A; Borrmann, S; Checchi, F; Davis, TME; Deloron, P; Ezzet, F; Faucher, JF; Fogg, C; Friberg Hietala, S; Guerin, PJ; Hamed, K; Karbwang, J; Karunajeewa, H; Kloprogge, F; Kofoed, PE; Lefèvre, G; Mårtensson, A; Mayxay, M; McGready, R; Mwai, L; Newton, PN; Ngasala, B; Nosten, F; Parikh, S; Piola, P; Price, RN; Proux, S; Salman, S; Stepniewska, K; Tarning, J; Tékété, M; Ursing, J; van Vugt, M; White, NJ; Workman, L, 2018) | 0.48 |
| " Simulations using the lumefantrine pharmacokinetic model suggest that, in young children and pregnant women beyond the first trimester, lengthening the dose regimen (twice daily for 5 days) and, to a lesser extent, intensifying the frequency of dosing (3 times daily for 3 days) would be more efficacious than using higher individual doses in the current standard treatment regimen (twice daily for 3 days)." | ( Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
Ashley, EA; Ashton, M; Aweeka, F; Bakshi, R; Barnes, KI; Björkman, A; Borrmann, S; Checchi, F; Davis, TME; Deloron, P; Ezzet, F; Faucher, JF; Fogg, C; Friberg Hietala, S; Guerin, PJ; Hamed, K; Karbwang, J; Karunajeewa, H; Kloprogge, F; Kofoed, PE; Lefèvre, G; Mårtensson, A; Mayxay, M; McGready, R; Mwai, L; Newton, PN; Ngasala, B; Nosten, F; Parikh, S; Piola, P; Price, RN; Proux, S; Salman, S; Stepniewska, K; Tarning, J; Tékété, M; Ursing, J; van Vugt, M; White, NJ; Workman, L, 2018) | 0.48 |
| "Our findings suggest that revised AL dosing regimens for young children and pregnant women would improve drug exposure but would require longer or more complex schedules." | ( Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
Ashley, EA; Ashton, M; Aweeka, F; Bakshi, R; Barnes, KI; Björkman, A; Borrmann, S; Checchi, F; Davis, TME; Deloron, P; Ezzet, F; Faucher, JF; Fogg, C; Friberg Hietala, S; Guerin, PJ; Hamed, K; Karbwang, J; Karunajeewa, H; Kloprogge, F; Kofoed, PE; Lefèvre, G; Mårtensson, A; Mayxay, M; McGready, R; Mwai, L; Newton, PN; Ngasala, B; Nosten, F; Parikh, S; Piola, P; Price, RN; Proux, S; Salman, S; Stepniewska, K; Tarning, J; Tékété, M; Ursing, J; van Vugt, M; White, NJ; Workman, L, 2018) | 0.48 |
| " This study used three screening methods and one confirmatory method for the quality assessment of 25 batches of artemether/lumefantrine dosage forms from the Ghanaian market to test that combined screening methods only can rapidly detect substandard and/or falsified medicines in areas where confirmatory methods may not be available." | ( Usefulness of combined screening methods for rapid detection of falsified and/or substandard medicines in the absence of a confirmatory method.
Amartey, SNA; Dzidonu, A; Larbi, MA; Nettey, H; Nti, G; Nyarko, AK; Opuni, KF; Owusu, NA; Owusu-Danso, P, 2019) | 0.51 |
| " These data suggest that malaria and HIV coinfected pregnant women may require adjustments in AL dosage or treatment duration to achieve exposure comparable with HIV-uninfected pregnant women." | ( Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
Aweeka, F; Huang, L; Hughes, E; Kajubi, R; Mwebaza, N; Mwima, MW; Nguyen, V; Nyunt, MM; Orukan, F; Parikh, S, 2020) | 0.56 |
| " Nineteen percent of HCPs thought that dihydroartemisinin/piperaquine gave the most satisfactory patient treatment outcomes, while 80% HCPs thought that artemether/lumefantrine gave the least satisfactory patient treatment outcomes, possibly due to dosing schedule and pill burden." | ( Healthcare professionals' perspective can guide post-marketing surveillance of artemisinin-based combination therapy in Uganda.
D'Hoore, W; Kiguba, R; Kirabira, E; Manirakiza, L; Mukonzo, J; Nabirye, L; Ndagije, HB; Olsson, S; Speybroeck, N; Spinewine, A; Sserwanga, A, 2020) | 0.56 |
| " This warrants further investigations of other drug-drug interactions for optimising dosing in genetically defined subgroups, particularly during drug development." | ( Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz.
Adeagbo, BA; Adegbola, AJ; Bolaji, OO; Bolarinwa, RA; Olagunju, AE; Owen, A; Rana, A; Siccardi, M, 2020) | 0.56 |
| " Additionally, these models are able to identify patient characteristics that cause alterations in the expected PK/PD profiles and through simulations can recommend changes to dosing which compensate for the differences." | ( Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations.
Hughes, E; Jagannathan, P; Mohamed Ali, A; Savic, RM; Wallender, E, 2021) | 0.62 |
| " Importantly, this would improve patient compliance due to decrease in dosing frequency as a sustained release formulation." | ( Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration.
Akpa, PA; Attama, AA; Echezona, AC; Ezeibe, EN; Kenechukwu, FC; Momoh, MA; Ugwu, CN; Ugwuoke, JA, 2020) | 0.56 |
| " Dosing is suboptimal in young children." | ( The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.
Aweeka, FT; Colt, M; Goodwin, J; Huang, L; Kajubi, R; Li, F; Mwebaza, N; Orukan, F; Parikh, S; Richards, K; Wang, K; Whalen, ME, 2023) | 0.91 |
| " Participants were randomly allocated 1:1 to antimalarial chemoprophylaxis, a 3-day course of twice-daily artemether-lumefantrine followed by the same daily dosing once a week while travelling in the forest and for a further 4 weeks after leaving the forest (four tablets per dose; 20 mg of artemether and 120 mg of lumefantrine per tablet), or a multivitamin with no antimalarial activity." | ( Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial.
Callery, JJ; Chotthanawathit, P; Conradis-Jansen, F; Dondorp, AM; Duanguppama, J; Ean, M; Heng, C; Imwong, M; Jongdeepaisal, M; Khonputsa, P; Madmanee, W; Maude, RJ; Mukaka, M; Peerawaranun, P; Pell, C; Peto, TJ; Pongsoipetch, K; Rekol, H; Sokha, M; Sovannaroth, S; Soviet, U; Tarning, J; Tripura, R; von Seidlein, L; Waithira, N; White, NJ, 2023) | 0.91 |
| " However, the optimal choice of medication and dosing for many potential candidates is not clear." | ( Modelling the optimal dosing schedule for artemether-lumefantrine chemoprophylaxis against malaria.
Dondorp, AM; Maude, RJ; Tarning, J; von Seidlein, L; White, NJ, 2022) | 0.72 |
| " However, the most favourable exposure profile, and arguably most practical dosing scenario, was an initial 3 day full AL treatment course followed by twice daily dosing given once a week for the duration of chemoprevention." | ( Modelling the optimal dosing schedule for artemether-lumefantrine chemoprophylaxis against malaria.
Dondorp, AM; Maude, RJ; Tarning, J; von Seidlein, L; White, NJ, 2022) | 0.72 |
| " Participants were randomly assigned (1:1) to receive single low-dose primaquine combined with either artemether-lumefantrine or dihydroartemisinin-piperaquine, dosed by bodyweight." | ( Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, n
Abongo, G; Basara, BB; Baseke, J; Bongo, GS; Day, NJP; Dhorda, M; Dondorp, AM; Fanello, C; Kayembe, DK; Maitland, K; Muhindo, R; Mukaka, M; Namayanja, C; Ndjowo, PO; Okalebo, CB; Olupot-Olupot, P; Onyamboko, MA; Onyas, P; Peerawaranun, P; Tarning, J; Taya, C; Taylor, WR; Titin, H; Uyoga, S; Waithira, N; Weere, W; Williams, TN, 2023) | 0.91 |
| " Parasite regrowth occurred after dosing with 200 mg (3/3 participants) and 300 mg (3/4 participants) but not after 400 mg or 600 mg." | ( Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum.
Abd-Rahman, AN; Barber, BE; Birrell, GW; Edstein, MD; Leelasena, I; Llewellyn, S; Marquart, L; McCarthy, JS; Moehrle, JJ; Potter, AJ; Sahai, N; Shanks, GD; Webster, R; Wesche, D, 2023) | 0.91 |
| "This retrospective, observational study explored associations between changing malaria service point (health facility or CHW) density per 1000 people and severe malaria admissions or malaria inpatient deaths by district and month in a dose-response approach, using existing routine and programmatic data." | ( Effectiveness of community case management of malaria on severe malaria and inpatient malaria deaths in Zambia: a dose-response study using routine health information system data.
Ashton, RA; Bennett, A; Burnett, S; Eisele, TP; Hainsworth, M; Hamainza, B; Lungu, C; Miller, JM; Porter, T; Rutagwera, MI; Silumbe, K; Slater, H, 2023) | 0.91 |
| " Robust training on appropriate anti-malarial and dosage is needed, particularly given the recent change in recommendation for artemether-lumefantrine use in the first trimester." | ( Healthcare provider and drug dispenser knowledge and adherence to guidelines for the case management of malaria in pregnancy in the context of multiple first-line artemisinin-based combination therapy in western Kenya.
Dellicour, S; Gutman, JR; Hill, J; Ochodo, E; Osoro, CB; Ter Kuile, F; Young, T, 2023) | 0.91 |